Modified Release Services at Quotient Sciences

In need of modified release formulation development?

We have global experience in designing modified-release formulations to meet the unique needs of our customers.

Get in touch

Quotient Sciences approach can get Modified Release (MR) drug products to patients in need, faster.

We understand that the demand for modified release formulations is driven by many factors related to both patient and therapeutic needs. We can help optimize drug delivery and balance therapeutic needs, manage AE profiles and reduce dosing frequency, which contribute to improved patient compliance.

Improve your outcome

Improve your outcome

With over 30 years of expertise, we can help with even the most challenging Modified Release programs.
Modified Release formats

Modified Release formats

Extensive experience in designing MR formulations, from gastro-retention to sustained & pulsatile release formats.
Translational Pharmaceutics®

Translational Pharmaceutics®

Utilize our unique integrated platform, Translational Pharmaceutics® to help accelerate the development of MR products.

Leverage the expertise of Quotient Sciences, to benefit your business

Adaptive, real-time capabilities

Using real-time, adaptive manufacturing and clinical testing, we are able to accelerate and re-risk development. This ultimately means that we can get our customer's Modified Release drug product to patients in need, faster.

Science driven approach

The science driven approach of using our unique Translational Pharmaceutic® to develop Modified Release products has been proven to accelerate and provide clinical benefit to patients worldwide.

Expert support

Although Modified Release formulations can offer many therapeutic benefits for customers and patients, there are several challenges that our scientific experts help overcome. We have over 30 years of expertise, and are ready to help with even the most challenging modified-release programs.

Download info sheet

MR formats

Quotient Sciences has extensive experience in designing modified release formulations, from gastro-retention to sustained and pulsatile release formats as outlined below.

Modified release format	Objective	Formulation technology
Gastro-retention	Keep the formulation in the stomach for an extended period to maximize the duration of absorption or therapeutic activity.	Swellable tablets (monolithic, bilayer, trilayer)
Gastric bypass	Prevent the release of the drug in the stomach and/or upper gastrointestinal tract. Overcome first-pass metabolism or gastric irritation.	Enteric coated tablets or capsules
Sustained or extended release	Extend the in vivo release profile of the drug or enable once-daily dosing.	Matrix tablets, coated tablets or multiparticulates
Targeted or controlled delivery	Release the drug at or near the intended site of absorption or action. Have either immediate or extended-release characteristics. Deliver time, pH or microbially-triggered release.	Tablets, capsules or multiparticulates
Biphasic release	Eliminate the need for repeat dosing. Provide rapid therapeutic effect from an immediate release layer and extended dosing via a sustained release layer.	Bilayer tablets or multiparticulates
Pulsatile release	Release the drug as a pulse after a predetermined lag time — designed according to the body’s circadian rhythm. Provide release mechanism beneficial for drugs where time-dependent dosing is required or those that undergo first-pass metabolism.	Bilayer tablets or multiparticulates

Achieve your drug program’s goals with one, integrated partner

Translational Pharmaceutics®

Integrated development platform that is proven to reduce timelines by >12 months.
Clinical Manufacturing

Clinical trial supplies for oral, injectable and inhaled dosage forms.
Clinical Pharmacology

Phase I healthy volunteer studies & 14C Human ADME.
Commercial Manufacturing

Tech transfer, Process Scale-Up & Optimization, Lifecycle Management.
Drug Substance

PR&D, Custom Synthesis and drug substance characterization.
Formulation Development

Simple & complex dosage forms: PIB, PIC, Tablets, Poorly Soluble, Modified-Release, Pediatrics.
Bioanalysis

Rapid bioanalytical data in discovery, pre-clinical & clinical.
Data Sciences

Rapid access to clinical data & results to accelerate drug development.
Consulting

Holistic scientific advice at each stage of drug development.

Customer success

Customer Testiomonials at Quotient Sciences

“The combination of GMP manufacturing and clinical testing within one organization was, as far as we are aware, entirely unique... The understanding we have gained through working with Quotient Sciences in terms of both the formulation development and the manufacturing will be invaluable.”

Dr David Hava, Chief Scientific Officer at Pulmatrix

Read case study

“The company’s ability to integrate manufacturing and dosing really accelerated the conduct of the study and was one of the main reasons that Corcept Therapeutics selected Quotient Sciences to undertake the study.”

Hazel Hunt, Chief Scientific Officer at Corcept Therapeutics

Read case study

“Quotient Sciences’ real-time manufacturing capabilities were a key factor in determining the speed at which this study could be concluded, offering the rare combination or GMP manufacturing and clinical administration on the same site, even for complex formulations and dosage forms. This allowed us to progress much faster.”

Dr Phil Collis, Vice President of Development at BioCryst Pharmaceuticals

Read case study

“My first response was this is too good to be true, they can’t do that. We’ve been looking for this type of solution for years – it can’t be done. However, we made a site visit and, within three days, accepted the proposal... We had clinical data within weeks... reducing the overall timeline by half, if not more.”

Deborah Gouveia, Vice President, Program & Alliance Management at Stealth BioTherapeutics

Read case study

“Quotient Sciences is an honest and straight-forward company with a very progressive attitude... What makes them unique is the way in which the pharmaceutical products are made on site and transferred, without leaving the building, to the clinical unit and a good, large and reliable pool of healthy volunteers.”

Gillian C. Ivers-Read, Former Executive VP & Chief Regulatory Officer of Clovis Oncology

Read case study

Who are Quotient Sciences?

More than a CDMO:CRO.

Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast. Because humanity needs solutions, fast.

About us Global customers FAQs Resources